Shop Easy Usa Ultram

Re: Beaulieu AD, Peloso PM, Haraoui B, et al. Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain to to osteoarthritis: a randomized controlled trial. Pain Res Manage 2008; 13:103-10, and Thorne C, Beaulieu AD, Callaghan DJ, et. al. A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis. Pain Res Manage 2008; 13:93-102.

Pain Res Manag. 2008 Jul-Aug;13(4):342

Authors: Champion P

PMID: 18816899 [PubMed - in process]

(Source: Pain Research and Management)

Orexo AB (OMX: ORX), the Swedish pharmaceutical company, announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Rapinyl, for breakthrough cancer pain. ProStrakan Group plc, the international speciality pharmaceutical is Orexo´s exclusive partner for sales and marketing of Abstral/Rapinyl in Europe.

Zogenix, Inc. ("Zogenix"), a private, specialty pharmaceutical company, announced that it will present successful results from two clinical studies of sumatriptan DosePro, a product in development for treatment of acute migraine and cluster headache, at the 50th Annual American Headache Society Meeting in Boston, Massachusetts.

Zogenix, Inc. ("Zogenix"), a private, specialty pharmaceutical company, announced that it will present successful results from two clinical studies of sumatriptan DosePro, a product in development for treatment of acute migraine and cluster headache, at the 50th Annual American Headache Society Meeting in Boston, Massachusetts.

Merck & Co., Inc. announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of migraine pain and migraine-associated symptoms two hours after dosing compared to placebo.

Great photo capsule on CD

ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of Abstral (formerly branded as Rapinyl), the fast-acting tablet for breakthrough cancer pain. ProStrakan plans to launch Abstral in Sweden in Q3 2008 and, as a result of today's announcement, across Europe from the end of 2008.

There are some 30 million Americans who suffer from migraine headaches.* Researchers at Ohio State University Medical Center have unveiled a new device that can control the pain of migraine headaches with no drugs, no injections, and no side effects. In fact this device is as easy as touching a button. After nearly eight years of development the migraine zapper could be on the market in a matter of months.

According to the National Institutes of Health, nearly 10 million Americans suffer from fibromyalgia. Sadly, many go through months and years of pain, frustration and confusion before receiving treatment because there is no diagnostic for this chronic illness. Medical tests such as x-rays, blood tests and muscle biopsies can rule out other medical conditions (lupus, rheumatoid arthritis, Lyme disease) but can't confirm fibromyalgia.

Headache frustrations are set to ease, thanks to a new range of patient leaflets. Produced by Lifting The Burden, the World Health Organization's Global Campaign to Reduce the Burden of Headache Worldwide, they will help sufferers understand and manage their headache more effectively. Almost all of us will have had a headache, but for many people it is more than just an irritant.